drugset / Trial / NCT03484923
Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of this study is to evaluate the efficacy of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma
Timeline
- Start
- 2018-09-10
- Primary completion
- 2022-12-30
- Completion
- 2022-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Canakinumab | Monoclonal antibody | 200 mg | Subcutaneous |
| Subject | Capmatinib | Small molecule | 400 mg | Oral |
| Subject | Ribociclib | Small molecule | 600 mg | Oral |
| Subject | Spartalizumab | Monoclonal antibody | 400 mg | Intravenous |
| Subject | ieramilimab | Monoclonal antibody | 600 mg | Intravenous |